Cargando…

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer

Small-cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by a rapid initial response and early development of resistance to systemic therapy and radiation. The management of SCLC significantly changed for the first time in decades with the introduction of immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riano, Ivy, Patel, Shruti R., Liu, Stephen V., Duma, Narjust
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293071/ https://www.ncbi.nlm.nih.gov/pubmed/34287275 http://dx.doi.org/10.3390/clinpract11030059

Ejemplares similares

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Stevens-Johnson Syndrome–Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer
por: Riano, Ivy, et al.
Publicado: (2020)

Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
por: McCusker, Michael G, et al.
Publicado: (2020)

Evaluating Internal Medicine Residents’ Awareness on Cancer Survivorship Care Plan: A Pilot Survey
por: Riano, Ivy, et al.
Publicado: (2022)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Liu, Qiao, et al.
Publicado: (2021)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
por: Chau, Vincent, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2021)

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
por: Tian, Wentao, et al.
Publicado: (2023)

The State of Cancer Care in Venezuela
por: Duma, Narjust, et al.
Publicado: (2019)

Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
por: Florez (DUMA), Narjust, et al.
Publicado: (2023)

Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
por: Cristancho, Cagney, et al.
Publicado: (2020)

Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

COVID-19 and Global Oncology: A Year in Review
por: Desai, Aakash, et al.
Publicado: (2021)

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
por: Gendarme, Sébastien, et al.
Publicado: (2022)

Immunotherapy for extensive stage small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: El Sayed, Rola, et al.
Publicado: (2021)

Race/Ethnicity and Gender Representation in Hematology and Oncology Editorial Boards: What is the State of Diversity?
por: Patel, Shruti R, et al.
Publicado: (2023)

Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam
por: Nguyen, Khanh Toan, et al.
Publicado: (2023)

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
por: Bylicki, Olivier, et al.
Publicado: (2020)

Radiation Therapy in Extensive Stage Small Cell Lung Cancer
por: Jeremic, Branislav, et al.
Publicado: (2017)

Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
por: Riano, Ivy, et al.
Publicado: (2023)

Exclusion of Male Patients in Breast Cancer Clinical Trials
por: Duma, Narjust, et al.
Publicado: (2018)

Primary neuroendocrine carcinoma of the brain
por: Reed, Clay T, et al.
Publicado: (2019)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy
por: Yang, Zhang-Ru, et al.
Publicado: (2020)

Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma
por: Oki, Rikako, et al.
Publicado: (2019)

Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2021)

Sociodemographic disparities in the management of advanced lung cancer: a narrative review
por: Stein, Jacob Newton, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Yang, Fang, et al.
Publicado: (2022)

Consolidative thoracic radiotherapy for extensive stage small cell lung cancer
por: Zhang, Xiaoli, et al.
Publicado: (2017)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
por: Powell, Kerrington, et al.
Publicado: (2021)

An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab
por: Bell, Sarah G., et al.
Publicado: (2021)

Real-World Outcomes of Nivolumab, Pembrolizumab, and Atezolizumab Treatment Efficacy in Korean Veterans with Stage IV Non-Small-Cell Lung Cancer
por: Ham, Ahrong, et al.
Publicado: (2023)

Timing of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer: important or not?
por: Luo, Jing, et al.
Publicado: (2017)

Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
por: Wang, Lan, et al.
Publicado: (2021)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Somasundaram, Ashwin, et al.
Publicado: (2017)

Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer
por: Baroz, Angel R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1m3avmlj0cpfa08d04j6lmehql